A practical reference on HGF/c-Met: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-02-18 and is reviewed periodically as new material appears.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
=== More complex general models === When developing more detailed models for in-depth analysis, models are mostly generated for specific outbreak scenarios of specific diseases, including compartments for targeted research questions like hospitalization compartments or detection dynamics. Even though those models are often tailored for specific situations, there are complex models, still usable for a broad variety of different diseases. One of those attempts to create a general model includes twelve compartments, extending the well-known SEIR model by a second stage of infection, detection compartments, and two doses of vaccination. Additionally smear infections are incorporated via an external Pathogen
== Awards and honors == 2023- Women's Empowerment Influencer Award Icahn School of Medicine at Mount Sinai 2017 – Elected Fellow of the American Society for Cell Biology 2015 – Senior Leadership Award of the Women in Cell Biology of the American Society for Cell Biology, named the Sandra K. Masur Leadership Award 2008 – Jacobi Medallion, Mount Sinai Alumni Association 2007 – Rosalind Franklin Society Invited Member of Founding Board 2001 Women in Medicine Silver Achievement Award, Association of American Medical Colleges 1997 Outstanding Woman Scientist – Association for Women in Science, Metropolitan New York Chapter 1997 Lew R. Wasserman Merit Award 1996 Outstanding Faculty Achievement Award 1978 Brotherhood Education Award, Conference of Christians and Jews
==== Droplet-based PCR ==== Polymerase chain reaction (PCR) has been a vital tool in genomics and biological endeavors since its inception as it has greatly sped up production and analysis of DNA samples for a wide range of applications. The technological advancement of microdroplet scale PCR has enabled the construction of single-molecule PCR-on-a-chip device. Early single molecule DNA replication, including what occurs in microdroplet or emulsion PCR, was more difficult than larger scale PCR so much higher concentrations of components were usually used. However, fully optimized conditions have minimized this overload by insuring single molecules have an appropriate concentration of replication components distributed throughout the reaction cell. Non-droplet based microfluidic PCR also faces challenges with reagent absorption into the device channels, but droplet-based systems lessen this problem with decreased channel contact. Using water-in-oil systems, droplet PCR operates by assembling ingredients, forming droplets, combining droplets, thermocycling, and then processing results much like normal PCR. This technique is capable of running in excess of 2 million PCR reactions in addition to a 100,000-fold increase in the detection of wild-type alleles over mutant alleles. Droplet-based PCR greatly increases the multiplexing capabilities of normal PCR – allowing for fast production of mutation libraries.
== Evolution == There are five groups of TNNI in vertebrates, the extra two known as TNNI4 and TNNI5 (only found in non-amniotes). They are more similar to TNNI1 than to TNNI2 and TNNI3. Likewise, there are four groups of TNNT in vertebrates, with TNNT4 (only found in cartilaginous fishes, ray-finned fishes and lungfish) most closely resembling TNNT2. In most vertebrates and some non-vertebrate chordates, TNNI and TNNT genes tend to occur in pairs next to each other. It is likely that an ancestor to vertebrates had one such pair, which was duplicated into four during the two rounds of whole-genome duplication in early vertebrate evolution, with TNNT5 arising as an additional tandem dupliaction of TNNT4. Most vertebrates express TNNI1 and/or TNNI5 in the heart, whereas adult tetrapods (such as mammals) use TNNI3. Embryonic mammals use TNNI1 in the heart. In humans and teterapods in general, TNNI3 differ from the other TnI genes by having an N-termianl extension; a strikingly similar extension is found in the TNNI5 of cartilaginous, non-teleost ray-finned, and sarcopterygian fishes. Ray finned fishes do not have TNNI3 at all. Substituting TNNI3 for TNNI1 may confer increased tolerance to acidosis. Considering the similarity between TNNI and TNNT, the gene pair may have been the result of an even more ancient tandem duplication event.
Reconnecting after years of estrangement, Enric and Irene confront their abusive past — discovering their father Albert lived a separate wealthy life and that Montserrat has continued her delusional cult. Enric infiltrates the family home during Christmas, exposing Montserrat’s lies, which culminates in Cecilia fleeing the household to join Irene. Following a visionary ayahuasca trip where Enric finally processes his childhood trauma while Irene and Cecilia rebuild their lives.
Sources: en.wikipedia.org
=== Juvenile breast hypertrophy === When gigantomastia occurs in pubescent females, the medical condition is known as juvenile macromastia or juvenile gigantomastia and sometimes as virginal breast hypertrophy or virginal mammary hypertrophy although the term virginal is now considered misleading and outdated. Along with the excessive breast size, other symptoms include red, itchy lesions and pain in the breasts. A diagnosis is made when an adolescent's breasts grow rapidly and achieve great weight, usually soon after their first menstrual period. Some doctors suggest that the rapid breast development occurs before the onset of menstruation. Some adolescents with juvenile breast hypertrophy experience breast growth at a steady rate for several years, after which the breasts rapidly develop exceeding normal growth. Some adolescent females experience minimal or negligible breast growth until their breasts suddenly grow very rapidly in a short period of time. This may cause considerable physical discomfort. Individuals with JBH often experience an excessive growth of their nipples as well. In severe cases of JBH, clitoromegaly occurs. At the onset of puberty, some females who have experienced little or no breast development can reportedly reach three or more cup sizes within a few days (see below). As of 1992, 70 cases of juvenile breast hypertrophy had been reported.
=== Early prototypes and barriers to entry: 1920s–1990s === In 1927, Joseph Robinson applied for a patent for an electronic vaporizer to be used with medicinal compounds. The patent was approved in 1930 but the device was never marketed. In 1930, the United States Patent and Trademark Office reported a patent stating, "for holding medicinal compounds which are electrically or otherwise heated to produce vapors for inhalation." In 1934 and 1936, further similar patents were applied for. The earliest e-cigarette can be traced to American Herbert A. Gilbert. In 1963, Gilbert applied for a patent for "a smokeless non-tobacco cigarette" that involved "replacing burning tobacco and paper with heated, moist, flavored air". This device produced flavored steam without nicotine. The patent was granted in 1965. Gilbert's invention was ahead of its time. However, it received little attention and was never commercialized because smoking was still fashionable at that time. Gilbert said in 2013 that today's electric cigarettes follow the basic design set forth in his original patent. The Favor cigarette, introduced in 1986 by public company Advanced Tobacco Products, was another early noncombustible product promoted as an alternative nicotine-based tobacco product. Favor was conceptualized by Phil Ray, one of the founders of Datapoint Corporation and inventors of the microprocessor. Development started in 1979 by Phil Ray and Norman Jacobson.
=== Nanoparticle-based Controlled-Release === The use of nanotechnology into drug delivery has opened the door to new possibilities, particularly with the development of nanoparticle-based controlled-release systems. These systems are designed to deliver drugs more precisely and over longer periods of time helping with targeted sites and therapeutic effects. Tiny carriers, such as liposomes, dendrimers, and polymeric nanoparticles, can hold medication and release them at controlled rates. Some are even engineered to respond to specific conditions in the body. For instance, acidic microenvironment commonly found in tumor tissues can be used to trigger drug release at the site needed. This targeted approach helps minimize side effects by limiting exposure to the rest the body. Thus, making treatment more effective. Recent studies have shown the effectiveness of smart nanoparticles that respond to biological cues, such as pH or redox conditions, thereby delivering drugs more precisely to tumor sites. For instance, pH-sensitive nanoparticles take advantage of the lower pH in tumor cells to release the drugs, which boost effectiveness while protecting healthy cells. Additionally, the use of biocompatible materials and switching the nanoparticle surfaces have improved their accuracy and release of delivery systems. Advances in design have also made it possible to create multi-functional nanoparticles that are capable of handling tough challenges like multi-drug resistance in cancer.
=== Chronic wounds === Any wound which is arrested or delayed during any of the normal stages of wound healing is considered to be a chronic wound. Most commonly, these are wounds which develop due to an underlying disease process such as diabetes mellitus or arterial/venous insufficiency. However, any acute wound has the potential to become a chronic wound if any of the normal stages of wound healing are interrupted. Chronic wounds are most commonly a result of disruption of the inflammatory phase of wound healing, however errors in any phase can result in a chronic wound. The exact duration of time which distinguishes a chronic wound from an acute wound is not clearly defined, although many clinicians agree that wounds which have not progressed for over three months are considered chronic wounds.
Amazon, with a 175,000 m² regional e-commerce fulfilment centre. Emtelle, with a $50 million telecoms and pipe manufacturing unit. noon.com, with a 252,000 m² regional e-commerce fulfilment centre. Metal Park, a 450,000 m² development with port and rail connectivity, spanning both free zone and mainland areas.
Sources: en.wikipedia.org
=== After World War II === After production was temporarily paused in the UK during World War II, Aero returned to market, introducing aerated chocolate to a generation which had never seen the product, and by 1950 a product containing aerated chocolate coating wafers was released. The war also impacted production in Canada and South Africa. Beginning in the late 1950s in an effort try to improve falling Aero sales, Rowntree's began releasing new varieties. These included coffee and orange varieties that were sold only briefly, but also included peppermint, which became a permanent fixture. Marketing for these products abandoned the emphasis on aerated chocolate as a "unique" type of chocolate, instead focusing on the "bubbly" structure.
== June 4, 1915 (Friday) == Third Battle of Krithia — British, French, and Indian forces made a third and last attempt to capture Achi Baba, the main position for Ottoman defenses on the Gallipoli peninsula but were beaten back, sustaining some 6,500 casualties. Ottoman casualties were higher, ranging between 9,000 and 10,000 men. The LZ 40, the first Zeppelin P Class airship of the Imperial German Navy, was flown to bomb targets in London. The Royal Norwegian Navy Air Service test flew the M.F.1 floatplane in Horten, Norway, the first Marinens Flyvebaatfabrikk model based on a design by Maurice Farman. The fraternity Alpha Sigma Nu was founded at Marquette University as an honor society for Jesuit colleges. Born: Modibo Keïta, Malian statesman, first President of Mali; in Bamako Coura, French Sudan (present-day Bamako, Mali) (d. 1977) Walter Hadlee, New Zealand cricketer, batman for the New Zealand national cricket team from 1937 to 1951; in Lincoln, New Zealand (d. 2006)
tonicity A measure of the effective osmotic pressure gradient of one solution relative to another solution, used especially to describe the water potential that exists between two aqueous solutions separated by a semipermeable membrane (as with a cell, where the intracellular cytosol is separated from the extracellular fluid by the plasma membrane). Tonicity depends on the relative concentrations of solutes on either side of the membrane, which determine the direction and extent to which solvent molecules move across the membrane by osmosis; it is affected only by those solutes which cannot cross the membrane, as those which can cross freely can achieve equilibrium without any net movement of solute. The extracellular environment is commonly described as hypotonic, hypertonic, or isotonic with respect to the intracellular environment.
This method is less efficient than blue LEDs with YAG:Ce phosphor, as the Stokes shift is larger, but it yields light with better spectral characteristics, which render color better. Due to the higher radiative output of the ultraviolet LEDs than of the blue ones, both methods offer comparable brightness. A concern is that UV light may leak from a malfunctioning light source and cause harm to human eyes or skin. A new style of wafers composed of gallium-nitride-on-silicon (GaN-on-Si) is being used to produce white LEDs using 200-mm silicon wafers. This avoids the typical costly sapphire substrate for relatively small 100- or 150-mm wafer sizes. The sapphire apparatus must be coupled with a mirror-like collector to reflect light that would otherwise be wasted. It was predicted that in 2020, 40% of all GaN LEDs are made with GaN-on-Si.
== Structure == β-acrosin demonstrates a high degree of sequence identity (70-80%) between boar, bull, rat, guinea pig, mouse, and human isoforms. There exists a somewhat similar (27-35%) sequence identity between β-acrosin and other serine proteases such as trypsin and chymotrypsin. While most serine proteases are activated through one cleavage event, proacrosin requires processing at both the N and C-terminal domains. Proacrosin is first cleaved between Arg-22 and adjacent Valine to create a 22 residue light chain, and an active protease termed α-acrosin. This light chain remains associated with the heavy chain, cross-linked through two disulfide bonds to form a heterodimer. Following these N-terminal cleavage events, three cleavages at the C-terminal domain removes 70 residues, yielding β-acrosin. Acrosin has two sites which have been identified as possible N-glycosylation sites: Asn-2 and Asn-169. The catalytic triad consists of residues His-57, Asp-102, and Ser-195. These residues are found in a binding pocket that has been termed the "S1" pocket, consistent with the naming scheme that has been adopted for other proteases. The S1 pocket regulates acrosin's specificity for Arg and Lys substrates, with a conserved Trp-215 serving as a "gatekeeper" residue for the binding site entrance.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.